口服有效的FDA批准的蛋白质激酶向共价抑制剂 (TCI):2025年更新
1Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, USA.
向的共价抑制剂对于通过不可逆转地阻断蛋白激酶来治疗疾病至关重要. 这些药物,像ibrutinib一样,为各种癌症和自身免疫性疾病提供有效的治疗方法.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 蛋白激酶异常与众多人类疾病有关,使它们成为重要的药物标.
- 向共价抑制剂的开发克服了以前对不可逆转药物机制的偏见.
研究的目的:
- 审查FDA批准的向共价抑制剂的作用机制和临床应用.
- 要突出共价抑制剂在药物开发中的日益重要.
主要方法:
- 对FDA批准的针对蛋白激酶的药物的审查.
- 分析涉及烯胺衍生物的共同共价结合机制.
主要成果:
- 美国食品和药物管理局批准了11种向共价抑制剂,包括布鲁顿氨酸激酶抑制剂 (ibrutinib,acalabrutinib,zanubrutinib),表皮生长因子受体抑制剂 (afatinib,dacomitinib,lazertinib,mobocertinib,osimertinib) 和其他向ErbB2,FGFR和JAK3.3的药物.
- 这些抑制剂具有共同的机制,即与蛋白质氨酸残留物形成乙烯键.
结论:
- 向共价抑制剂是一种有价值的,越来越受欢迎的治疗策略.
- 这些抑制剂对各种癌症和其他疾病的治疗产生了重大影响.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11:11Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Protein Kinases and Phosphatases
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Inhibition of Cdk Activity
PI3K/mTOR/AKT Signaling Pathway
